---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-014914"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:10:39.022386+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aquestive Q1 net income $8.1M vs loss; raises FY revenue guidance to $42-46M

## Summary
- Net income $8.1M ($0.11 diluted EPS) vs net loss $13.2M ($0.32 loss) in Q1 2022.
- Total revenue $11.1M, down from $12.3M YoY; excluding prior Sympazan sales, revenue +10%.
- Non-GAAP adjusted EBITDA loss improved to $3.9M from $8.1M.
- Raises FY2023 guidance: revenue $42-46M (prev. $37-41M); adj EBITDA loss $24-28M (prev. $31-36M).
- Two shareholder lawsuits dismissed with prejudice in April 2023; brand name Anaphylm conditionally accepted by FDA.

## SEC filing metadata
- accession: 0001628280-23-014914
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828023014914/0001628280-23-014914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828023014914/aqst-20230502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-014914
- JSON: https://secwatch.observer/filing/0001628280-23-014914.json
- Plain text: https://secwatch.observer/filing/0001628280-23-014914.txt

## Key facts
- Earnings Releases
  Aquestive Therapeutics, Inc. updated its first quarter ended March 31, 2023 guidance (raised).
  - Period: first quarter ended March 31, 2023
  - Guidance: raised
  - Result: reported results
  source text: On May 2, 2023, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing its reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments in its business.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000162828023014914/0001628280-23-014914-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.